Q2 2026 saw 14.8% comparable sales growth to $12.6B and adjusted EPS of $1.312, beating expectations. Full-year sales growth guidance was reaffirmed at 6.5–7.5%, and adjusted EPS guidance was raised. Key innovations advanced in diagnostics and diabetes care.Original document: Abbott Laboratories [A…
Q2 2026 saw 14.8% comparable sales growth to $12.6B and adjusted EPS of $1.312, beating expectations. Full-year sales growth guidance was reaffirmed at 6.5–7.5%, and adjusted EPS guidance was raised. Key innovations advanced in diagnostics and diabetes care.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
